Denali Therapeutics Inc. (DNLI) › Capital ExpendituresDenali Therapeutics Inc. (DNLI) — Capital ExpendituresAnnual figures by period end, from SEC filings.2016-12-31: $6.13M2017-12-31: $2.88M2018-12-31: $3.39M2019-12-31: $17.92M2020-12-31: $3.10M2021-12-31: $8.50M2022-12-31: $17.83M2023-12-31: $12.94M2024-12-31: $15.91M2025-12-31: $9.50M$9.50M2016-12-31Capital Expenditures (USD)2025-12-31Period endedCapital ExpendituresChange YoYSource filing2025-12-31$9.50M-40.3%2026-02-26From 2025-01-012024-12-31$15.91M+23.0%2026-02-26From 2024-01-012023-12-31$12.94M-27.4%2026-02-26From 2023-01-012022-12-31$17.83M+109.8%2025-02-27From 2022-01-012021-12-31$8.50M+174.6%2024-02-28From 2021-01-012020-12-31$3.10M-82.7%2023-02-27From 2020-01-012019-12-31$17.92M+428.1%2022-02-28From 2019-01-012018-12-31$3.39M+18.0%2021-02-26From 2018-01-012017-12-31$2.88M-53.1%2020-02-27From 2017-01-012016-12-31$6.13M—2019-03-12From 2016-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)